Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Budget Flat In House Bill, But Path For 'Cures' Funding Cleared

Executive Summary

US agency's budget authority would remain at current level under FY 2018 appropriations bill reported out by a House subcommittee; measure includes language enabling FDA's Oncology Center of Excellence to receive 21st Century Cures funding transferred from National institutes of Health.

You may also be interested in...



US FDA May Create Immunology, Neuroscience Centers Of Excellence

Commissioner Gottlieb says new centers would follow template of Oncology Center of Excellence.

Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?

Appropriations bill report includes language stating that it is 'imperative' the agency take all steps necessary to require opioid prescriber training.

FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff

No additional hiring is expected as US agency announces formal plan to return orphan review times to the original 90-day goal.

Related Content

Topics

UsernamePublicRestriction

Register

PS120988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel